Less than 5 percent of prescribers account for half of all buprenorphine treatment in the country
Improvement seen in treatment satisfaction and several secondary end points for depot buprenorphine versus sublingual buprenorphine
Differences between the two trajectories persist in opioid fills, misuse beyond 12 months
8-mg dose of naloxone hydrochloride nasal spray now approved with 2-mg and 4-mg doses